Marwar Anaga, Shaker Ivvala Anand, Palawan Hemraz, Ranjith M S
Department of Pharmacology, P.I.M.S RMC Loni, Ahmednagar, Maharashtra, India.
Department of Clinical Biochemistry, P.I.M.S RMC Loni, Ahmednagar, Maharashtra, India.
J Basic Clin Pharm. 2010 Dec;2(1):27-32. Epub 2011 Feb 15.
Emergence of extensively drug resistant tuberculosis (XDR-TB) has been reported by more than 55 countries. XDR-TB is considered as untreatable and highly fatal disease. In developing countries like India, number of cases of multi-drug resistant tuberculosis (MDR-TB) and XDR-TB are increasing. Emergence of resistance to Isoniazid and Rifampicin, the two most effective and well tolerated agents, coupled with resistance to second line agents pose limited treatment options for XDR-TB. The present minireview provides information about the seriousness of XDR-TB and the drugs available for its treatment. Although considered a fatal disorder, judicious use of combination of drugs, retaining their antimycobacterial activity, can improve the clinical outcome of XDR-TB. Only such an approach can provide some hope for the patients of XDR-TB.
超过55个国家报告了广泛耐药结核病(XDR-TB)的出现。XDR-TB被认为是无法治疗且高度致命的疾病。在印度这样的发展中国家,耐多药结核病(MDR-TB)和XDR-TB的病例数正在增加。对两种最有效且耐受性良好的药物异烟肼和利福平产生耐药性,再加上对二线药物的耐药性,使得XDR-TB的治疗选择有限。本综述提供了有关XDR-TB的严重性及其治疗可用药物的信息。尽管被认为是一种致命疾病,但明智地使用保留其抗分枝杆菌活性的联合药物,可以改善XDR-TB的临床结果。只有这样的方法才能给XDR-TB患者带来一些希望。